- PCOS affects 10 to 13 percent of women worldwide and is diagnosed when two of three features are present, once other causes are excluded (1).
- It was never a disease of cysts. The condition reaches into insulin, blood fats, sleep and mood, which is why the name misled (1, 3).
- On 12 May 2026 a global consensus renamed it polyendocrine metabolic ovarian syndrome, PMOS (3, 4). The criteria did not change, so a diagnosis made under the old name stands.
- Almost half of women see three or more professionals before they are diagnosed (5). Knowing the criteria shortens that road.
A syndrome, not a disease, and not about cysts
PCOS is a syndrome: a cluster of features that tend to occur together, not one disease with one cause. The 2023 International Evidence-based Guideline, the document doctors in Europe, North America and Australia now work from, describes a condition in which the ovaries, the adrenal glands, insulin and the brain's hormone signals interact, with effects that reach well past the reproductive system (1).
The old name misled twice. The "cysts" seen on ultrasound are small follicles, eggs that paused before ovulation, and the experts behind the 2026 renaming state plainly that there is no increase in abnormal cysts on the ovary in this condition (3). And the ovaries are only one organ of several involved. The guideline itself endorsed the 2012 verdict of a National Institutes of Health workshop that the name "is a distraction and should be changed" (1). Fourteen years later, it was.
How many women have it
Using the Rotterdam criteria, the guideline puts the prevalence at 10 to 13 percent of women worldwide, across all ethnicities and regions (1). A meta-analysis of prevalence studies found 6 percent under the stricter 1990 criteria and 10 percent under the Rotterdam and Androgen Excess Society criteria, which is why older sources quote lower numbers (2). The Endocrine Society's 2026 announcement speaks of about one woman in eight, around 170 million people (3).
Prevalence is similar across ethnic groups, but the features differ: the guideline asks doctors to account for ethnic variation in how the condition shows and in metabolic risk (1). The World Health Organization estimates that up to 70 percent of affected women remain undiagnosed (6). If you suspect it, you are not being dramatic; you are in a large and under-counted group.
The three features, and the rule of two
For an adult, the guideline requires two of these three features, after other causes have been excluded (1):
- Irregular cycles or missing ovulation. More than three years after the first period, a cycle shorter than 21 or longer than 35 days, or fewer than eight cycles a year, counts as irregular; so does any single cycle longer than 90 days. Ovulation can also fail with regular cycles, which a progesterone test can show (1).
- High androgens. Either clinical signs assessed by a doctor, or raised androgens in a blood test taken with the right method (1). The blood tests article covers how.
- Polycystic ovarian morphology, or a raised AMH. Many small follicles on ultrasound, or, new since 2023, a raised anti-Müllerian hormone level in adults as an alternative to the scan. Not both: the guideline asks for one or the other, to limit overdiagnosis (1).
If the first two are present, no ultrasound and no AMH are needed. "Excluding other causes" means a thyroid test, prolactin, 17-hydroxyprogesterone, and FSH and LH where periods have stopped, because each of those can imitate PCOS (1).
Why teenagers are assessed differently
Within eight years of the first period, the guideline requires both irregular cycles and high androgens, and it does not use ultrasound or AMH at all, because many follicles and variable cycles are normal in young ovaries (1). A teenager with only one feature is described as "at risk", with a reassessment later rather than a label now (1).
The pill complicates the picture at any age. It raises the protein that binds testosterone and lowers androgen production, so androgen results on the pill cannot be judged; if the test is essential, the guideline says to stop the pill for at least three months first, with other contraception meanwhile (1). Women who started the pill young, with features already present, should be reassessed at reproductive maturity (1).
Beyond the ovaries: insulin, heart, sleep, mood
This is the part the old name hid. The guideline calls insulin resistance a pathophysiological factor in PCOS (1), and women with the condition have a higher risk of impaired glucose tolerance and type 2 diabetes regardless of age and weight, which is why glucose should be checked at diagnosis and every one to three years (1). Cardiovascular risk is raised (1). Obstructive sleep apnea is more common independent of BMI (1), and across 18 studies with 16,152 participants, women with PCOS had about six times the odds of disturbed sleep (7).
The guideline also asks doctors to screen every woman with PCOS for depressive and anxiety symptoms, and to be aware of eating disorders and body-image distress (1). None of this means every woman has every feature. It means the condition deserves a full assessment, not a prescription and a pat on the shoulder. Insulin resistance has an article of its own.
What changed on 12 May 2026: PMOS
On 12 May 2026, a multistep global consensus process published in The Lancet renamed the condition polyendocrine metabolic ovarian syndrome, PMOS (4). More than 50 patient and professional organizations took part, led by Helena Teede, who also led the guideline, and Terhi Piltonen of the Androgen Excess and PCOS Society (3). "Polyendocrine" names the several hormone systems involved, "metabolic" names insulin and the heart, and "ovarian" keeps the organ where the diagnosis is often first suspected.
What did not change: the diagnostic criteria, the tests, the treatments, and your diagnosis. The new name is being phased in, so for a while you will see both on lab forms, in apps and in search results (3). When you search for information, try both terms. When your doctor writes the old one, nothing is wrong.
The road to a diagnosis, and how to shorten it
In a survey of 1,385 women, 47 percent had seen three or more health professionals before being diagnosed, and only 15.6 percent were satisfied with the information they received at diagnosis (5). The guideline treats this as a problem to solve: it asks for education, shared decisions and a lifelong plan rather than a one-line verdict (1).
You can shorten your own road with four things. Know the rule of two and say it out loud at the appointment. Bring the dates of your last three bleeds and your medication list, including the pill. Ask for the blood tests that confirm or exclude the look-alikes, which the free checklist lists with their sources. And ask for a printed copy of every result with its reference range, so the next doctor does not start from zero.
What coaches can do with this, and what they cannot
Coaches cannot diagnose. What the guideline hands to people like us is its first recommendation on management: lifestyle support, meaning exercise alone or diet combined with exercise, should be recommended to all women with PCOS, with benefits even when weight does not change (1). That is the ground HERA's documents stand on: training written for your week, meals built without food rules, supplement education checked against your medication, and a blood test guide for the appointment, all alongside your medical care.
Keep reading with the blood tests, or go straight to what to eat.
Only a doctor can diagnose PCOS. This article is information from certified coaches, not medical advice, and it does not replace a consultation.
References
- Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108(10):2447-2469. doi.org/10.1210/clinem/dgad463
- Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2841-2855. doi.org/10.1093/humrep/dew218
- Endocrine Society. Polyendocrine Metabolic Ovarian Syndrome: new name to improve diagnosis and care of condition affecting 170 million women worldwide. Press release, 12 May 2026. endocrine.org
- Teede HJ, Khomami MB, Morman R, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026. doi.org/10.1016/S0140-6736(26)00717-8
- Gibson-Helm M, Teede H, Dunaif A, Dokras A. Delayed diagnosis and a lack of information associated with dissatisfaction in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2017;102(2):604-612. doi.org/10.1210/jc.2016-2963
- World Health Organization. Polycystic ovary syndrome, fact sheet. 2023. who.int
- Zhang J, Ye J, Tao X, Lu W, Chen X, Liu C. Sleep disturbances, sleep quality, and cardiovascular risk factors in women with polycystic ovary syndrome: systematic review and meta-analysis. Front Endocrinol. 2022;13:971604. doi.org/10.3389/fendo.2022.971604